Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2006 Aug;65(8):1006-12.
doi: 10.1136/ard.2005.048371. Epub 2006 Jan 5.

Safety of extended treatment with anakinra in patients with rheumatoid arthritis

R M Fleischmann  1 , J Tesser, M H Schiff, J Schechtman, G-R Burmester, R Bennett, D Modafferi, L Zhou, D Bell, B Appleton
Affiliations
Randomized Controlled Trial

Safety of extended treatment with anakinra in patients with rheumatoid arthritis

R M Fleischmann et al. Ann Rheum Dis. 2006 Aug.

Abstract

Objective: To determine the safety profile of anakinra after extended exposure in a diverse clinical trial population of patients with rheumatoid arthritis.

Methods: A six month, randomised, double blind phase comparing anakinra (100 mg/day) with placebo was followed by open label anakinra treatment for up to three years in patients with rheumatoid arthritis. Concomitant non-steroidal anti-inflammatory drugs, corticosteroids, and other disease modifying antirheumatic drugs were permitted.

Results: In all 1346 patients with rheumatoid arthritis received anakinra for up to three years. Patients had varying levels of disease severity, concomitant drug use, and comorbid conditions. Cumulative, exposure adjusted event (EAE) rates for all adverse events (AEs), serious AEs, and deaths were similar during each year of anakinra treatment; the overall rate (0 to 3 years) was similar to that observed for controls during the blinded phase. The most frequent AEs were injection site reactions (122.26 events/100 patient-years), rheumatoid arthritis progression (67.80 events/100 patient-years), and upper respiratory infections (26.09 events/100 patient-years). The EAE rate of serious infections was higher for patients treated with anakinra for 0 to 3 years (5.37 events/100 patient-years) than for controls during the blinded phase (1.65 events/100 patient-years). However, if the patient was not receiving corticosteroid treatment at baseline, the serious infection rate was substantially lower (2.87 event/100 patient-years). The overall incidence of malignancies was consistent with expected rates reported by SEER. Neutralising antibodies developed in 25 patients, but appeared to be transient in 12; neutralising antibody status did not appear related to occurrence of malignancies or serious infections. There were no clinically significant trends in laboratory data related to anakinra.

Conclusion: Anakinra is safe and well tolerated for up to three years of continuous use in a diverse population of patients with rheumatoid arthritis.

PubMed Disclaimer

References

    1. Bakker A C, Joosten L A, Arntz O J, Helsen M M, Bendele A M, van de Loo F A.et al Prevention of murine collagen‐induced arthritis in the knee and ipsilateral paw by local expression of human interleukin‐1 receptor antagonist protein in the knee. Arthritis Rheum 199740893–900. - PubMed
    1. Otani K, Nita I, Macaulay W, Georgescu H I, Robbins P D, Evans C H. Suppression of antigen‐induced arthritis in rabbits by ex vivo gene therapy. J Immunol 19961563558–3562. - PubMed
    1. Joosten L A, Helsen M M, van de Loo F A, van den Berg W B. Anticytokine treatment of established type II collagen‐induced arthritis in DBA/1 mice. A comparative study using anti‐TNF alpha, anti‐IL‐1 alpha/beta, and IL‐1Ra. Arthritis Rheum 199639797–809. - PubMed
    1. Bresnihan B, Alvaro‐Gracia J M, Cobby M, Doherty M, Domljan Z, Emery P.et al Treatment of rheumatoid arthritis with recombinant human interleukin‐1 receptor antagonist. Arthritis Rheum 1998412196–2204. - PubMed
    1. Nuki G, Bresnihan B, Bear M B, McCabe D. Long‐term safety and maintenance of clinical improvement following treatment with anakinra (recombinant human interleukin‐1 receptor antagonist) in patients with rheumatoid arthritis: extension phase of a randomized, double‐blind, placebo‐controlled trial. Arthritis Rheum 2002462838–2846. - PubMed

Publication types

MeSH terms